Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vivacelle Bio Receives $5.3M from the US Navy to Study VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivacelle Bio\u2019s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Vivacelle Bio

    Menu

    Vivacelle Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vivacelle Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

              Details:

              VBI-S, used in the hypovolemia of septic shock is that it absorbs nitric oxide, a gas produced in excess by the body during hypovolemic shock and that contributes significantly to the drop in blood pressure when volume is lost inside the blood vessels.

              Lead Product(s): VBI-S

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: VBI-S

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivacelle Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivacelle Bio Receives $5.3M from the US Navy to Study VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

              Details:

              Vivacelle's VBI-S is likely to be effective in elevating blood pressure to survivable levels and improving oxygenation at early and even late stages of septic shock when current therapy, consisting of fluids and vasopressor medications, have failed.

              Lead Product(s): VBI-S

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: VBI-S

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: US Navy

              Deal Size: $5.3 million Upfront Cash: Undisclosed

              Deal Type: Funding November 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY